Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

Short term intensive insulin therapy followed by Insulin Glargine and Lixisenatide Injection(iGlarLixi) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.

Short term intensive insulin therapy followed by Insulin Degludec and Insulin Aspart Injection(IDegAsp) for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.

Short term intensive insulin therapy followed by Insulin Glargine Injection(iGlar） plus metformin 0.5g tid for 24 weeks. After then, participants continue with the current treatment or downgrade to the original treatment before enrollment for 24 weeks based on their own will. The total follow-up period was 48 weeks.